Skip to main content
Conference Coverage

Maternal and Neonatal Safety of Taxane Chemotherapy During Pregnancy for the Treatment of Breast Cancer

Featuring Ana Ferrigno, MD

 

Ana Ferrigno, MD, Yale University School of Medicine, New Haven Connecticut, discussed results from an international cohort study which determined that the use of taxane-containing chemotherapy during pregnancy does not increase the risk of obstetric and neonatal complications.

 These results were first presented at the 2023 San Antonio Breast Cancer Symposium.


Source:

Ferrigno Guajardo A, Vaca-Cartagena B, Mayer E, et al. Safety of taxane chemotherapy for the treatment of breast cancer during pregnancy: An international cohort study. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract PS13-03

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.